Analyst Price Targets — ATRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 8, 2026 8:49 am | — | Canaccord Genuity | $13.00 | $9.93 | TheFly | Atara Biotherapeutics upgraded to Buy from Hold at Canaccord |
| January 13, 2026 6:37 pm | — | New Street | $6.00 | $4.42 | TheFly | Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier) |
| December 19, 2025 11:28 am | — | Canaccord Genuity | $25.00 | $17.23 | TheFly | Atara Biotherapeutics price target raised to $25 from $17 at Canaccord |
| November 13, 2024 2:10 pm | Benjamin Burnett | Stifel Nicolaus | $10.00 | $7.58 | StreetInsider | Atara Biotherapeutics (ATRA) PT Raised to $10 at Stifel |
| August 16, 2024 8:55 am | Salim Syed | Mizuho Securities | $18.00 | $6.83 | TheFly | Mizuho upgrades Atara to Buy into potentially better 2025 |
| August 9, 2022 8:38 am | — | Goldman Sachs | $3.00 | $3.87 | Benzinga | Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $3 |
| May 24, 2022 7:31 am | — | Goldman Sachs | $4.00 | $4.85 | Benzinga | Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $4 |
Latest News for ATRA
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2026 and business updates. “This was an important quarter for Atara. We and our…
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors. “On behalf of Atara and its Board of Directors, I want…
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient has been dosed in QUATRO-APL, the company's global Phase 3 clinical trial evaluating QTX-2101, an investigational oral capsule formulation of arsenic trioxide, in combination with all-trans retinoic acid (ATRA), for the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ATRA.
U.S. House Trading
No House trades found for ATRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.